Lovo-Luc

305682

GENERAL INFORMATION

Description

LoVo-Luc □□□ LoVo □□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□ LoVo □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□□ 56 □□ □□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□ LoVo □□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ (MSI), □□□□□□□□□□□□□□□□□□□□□□□□□□□□ (dMMR), □□□ □□□□□□□□□□□□□□□□□□□□□□□□□ □□□□ Myc, myb, ras, fos □□□ p53. □□□□□□□□□□□□□□□□□□□□□□□ LoVo □□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ (mismatch repair) □□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□
□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ LoVo-Luc □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ (BLI) □□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□ (xenograft) □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ LoVo-Luc □□ □□□ □□□□□□□□□□□ (immune checkpoint inhibitors), □□□□□□□□□□□□□ (chemotherapeutic agents), □□□□□□□□□□□□□□□□□□□□□□ (targeted therapies) □□ □□□□□□□□□□□ (MMR-deficient colorectal cancer) □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ (high-throughput drug screening) □□
LoVo-Luc □□ LoVo □□□□□□□□□□ □□□□□□□□□ □□□□□□ MSI, □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ (CEA) □□ □□□□□□□□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□ MMR □□ □□□

Tissue	□□□□□□□□□□
Disease	□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□
Metastatic site	□□□

CLASSIFICATION

Organism	Human
Sex	Male
Growth properties	Adherent
GMO status	GMO-S1

GMO status details

GMO-S1: This cell line contains a stably integrated firefly luciferase reporter cassette (Luc2, codon-optimized) introduced via replication-incompetent lentiviral transduction. The resulting polyclonal cell population was maintained under puromycin selection (1–5 µg/mL). S1 containment is required. This classification applies only within Germany and may differ elsewhere.

Biosafety level	1

CHARACTERISTICS

Morphology	□□□□□□□□□□□□□□□□□□□□□□
Tumourigenic	□□□ □□□□□□□□□□□□□□□□
Doubling time	24-48 □□□□□□□□

IDENTIFIERS

Citation

Lovo-Luc (□□□□□□□□□□□□□□□□□□□□ Cytion 305682)

NCBI TaxID	9606
Cellosaurus	CVCL_4Y03

EXPRESSION AND SUSCEPTIBILITY

Antigen expression

HLA A11, B15, B17, Cw1, Cw3, □□□□□□□□□□ B, Luc2 (□□□□□□□, □□□□□□□□□□□□□□□□□□□□□□□□□□□□)

Isoenzymes

G6PD, B, PGM1, 2, PGM3, 1-2, 6PGD, A, ES-D, 1

Oncogenes

Myc +, myb + , ras +, fos +, p53 +, sis -, abl -, ros -, src -

Mutational profile

□□□□□□□□□□□□□□□: p.Lys437Argfs*5, □□□□□□□□□□□□□□□; □□□□□□□□□□□□□□□: p.Arg1114Ter, □□□□□□□□□□□□□□□; □□□□□□□□ □□□□□□□: p.Met1431fs*42, □□□□□□□□□□□□□□□; □□□□□□□□□□□□□□□: p.Arg2816Gln, □□□□□□□□□□□□□□□; □□□□□□□□□□□□□□□: p.Leu15Phefs*41, □□□□□□□□□□□□□□□; □□□□□□□□□□□□□□□: p.Arg505Cys, □□□□□□□□□□□□□□□; □□□□□□□□□□□□□□□: p.Gly13Asp, □□ □□□□□□□□□□□□; □□□□□□□□□□□□□□□: p.Ala292Val, □□□□□□□□□□□□□□□; □□□□□□□□□□□□□□□: p.Lys128Serfs*35, □□□□□□□□□□

Reverse transcriptase	□□□□□□

Products

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ (CEA) 908 □□□□□□□□□/10^6 □□□□□/10 □□□

HANDLING AND CULTURE

Culture medium

Ham's F12K Medium, w: 2.0 mM L-Glutamine, w: 2.0 mM Sodium pyruvate, w: 2.5 g/L NaHCO3 (□□□□□□□□□□□□□□□ Cytion 820608a)

Incubation atmosphere	37°C, 5%CO2, □□□□□□□□□□□□□□

Supplements

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ FBS 10%

Dissociation reagent	□□□□□□□□□

Subculturing

[illegible] PBS [illegible] T25 [illegible] PBS 3-5 [illegible]. [illegible] T75 [illegible] 5-10 [illegible]. [illegible] Accutase [illegible] 1-2 [illegible]. [illegible] T25 [illegible] 2.5 [illegible]. [illegible] T75[illegible] 8-10 [illegible] 10 [illegible] 300 [illegible] (300xg) [illegible] 3 [illegible]

Split ratio	1 [illegible] 3
Seeding density	1–3 × 10^4/cm²
Fluid renewal	2 [illegible] 3 [illegible]

Thawing and culturing

Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.
Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.
For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.
Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.
Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.
Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.
Follow the procedure described under Post-Thaw Recovery

QUALITY CONTROL AND CRYOPRESERVATION

Freeze medium	[illegible] + 10% DMSO [illegible]

Storage conditions

[illegible] −150 [illegible] −196 °C [illegible] −80 °C [illegible]

Shipping conditions

[illegible] −78 °C [illegible]

DONOR

Donor age	56 [illegible]
Ethnicity	[illegible]

LEGAL AND SAFETY

Safety precautions

[illegible]

Warranty

□□□Cytion □□
□□
60 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□
□□
□□□□□□□□□□□□□□□□□□□□□ □□□/□□□□□□□□□□□□□□□□□□□□□□□□□□
□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□
<a href=""/Who-we-are/Warranty/"" hreflang=""x-default"">□□□□□□□□□□□□□□□□□□□□.

Material Transfer Agreement required	Yes

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB